Desarrollado por: Instituto de Investigación Biomédica de Bellvitge (IDIBELL)



Lack of clinical test to classify the origin of the sperm defects in semen


Non-invasive biomarkers to diagnose azoospermia origin


• Non-invasive azoospermia biomarkers & Kit development

• High sensitivity and specificity (>90%)

• Effective azoospermia test in seminal plasma to avoid unnecessary biopsies.


This group of miRNAs could be used as non-invasive biomarkers that contribute in the diagnosis of the origin of azoospermia.

Those azoospermic cases predicted to be originated from an obstruction of the genitourinary tract have many chances to obtain sperm from the testicular biopsy for the assited reproduction treatment.

Additionally, several miRNAs could be used as non-invasive biomarkers to predict the presence of spermatozoa in secretory azoospermia in order to avoid unnecessary biopsies.

Estado de protección

Semen samples were obtained from normozoospermic (Nz) fertile individuals (control group); individuals with obstructive azoospermia (OA) with conserved spermatogenesis including both, men successfully vasectomized (OA-V) and individuals presenting pathological naturally occurring- obstruction in the genital tract (OA-N); and infertile man diagnosed with secretory azoospermia (SA) (no sperm in semen sample due to spermatogenic failure).

We have determined one miRNA that is able to distinguish azoospermic samples derived from a spermatogenic disorder from those derived from an obstruction with high sensitivity and specificity (>90%). The efficacy of the predictive test was even better when the blood FSH values were included in the analysis. Additionally, the combination of expression data of two miRNAs is able to discriminate those secretory azoospermic samples without a reserve of sperm in the testis with a 100% of specificity and sensitivity.

Moreover, the kit technology is currently being developed in order to create an easy to use and cheap kit to determine the azoospermia origin.

TRL: Technology validated in the lab
IP: Patent application EP18382194

Cooperación que se desea


License agreement


Responsable: Área de Desarrollo de Negocio e Innovación // Oficina de Transferencia de Tecnología

Contacto (Tel./mail): 93 260 71 06 / Innovacio@idibell.cat

En desarrollo, Transferible
Tecnología sanitaria:
Biotecnología y Diagnóstico Molecular (proteómica, genómica, etc...)